- Home
- ATGE vs PCVX Comparison
ATGE vs PCVX Comparison
Compare ATGE & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATGE | PCVX |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATGE | PCVX |
|---|---|---|
| Price | $101.04 | $46.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $145.67 | $101.67 |
| AVG Volume (30 Days) | 676.7K | ★ 1.5M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.29 | N/A |
| EPS | ★ 6.69 | N/A |
| Revenue | ★ $1,833,178,000.00 | N/A |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | ★ 12.24 | N/A |
| 52 Week Low | $86.11 | $27.66 |
| 52 Week High | $156.26 | $93.77 |
Technical Indicators
Market Signals| Indicator | ATGE | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 54.15 |
| Support Level | $98.97 | $42.40 |
| Resistance Level | $102.32 | $45.15 |
| Average True Range (ATR) | 2.53 | 1.95 |
| MACD | 2.17 | -0.30 |
| Stochastic Oscillator | 87.78 | 68.65 |
Price Performance
Historical ComparisonAbout ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.